Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety and efficacy study of donidalorsen for prophylactic treatment of hereditary angioedema
NL-OMON53420Phase 3Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2022
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of donidalorsen in hereditary angioedema (HAE), sponsored by Ionis Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Nov 2022; status: recruiting.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON53420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53420.